Pfizer weight reduction tablet strikes ahead as once-daily model

Pfizer on Thursday stated it would transfer ahead with a once-daily model of its weight reduction tablet, danuglipron, after it noticed “encouraging” information in an ongoing early-stage research.

The corporate evaluated a number of once-daily formulations of the drug and recognized one with “probably the most favorable profile” by way of security and the way the physique reacts to the drug.

Pfizer stated it plans to conduct extra early-stage trials within the second half of the 12 months to establish the best dose of the drug, with outcomes anticipated within the first quarter of subsequent 12 months, a spokesperson advised CNBC. The corporate stated these trials will “inform the registration enabling research,” that are utilized in purposes for regulatory approval.

Outcomes are anticipated within the first quarter of subsequent 12 months, a spokesperson advised CNBC.

Danuglipron “has demonstrated good efficacy in a twice-daily formulation, and we imagine a once-daily formulation has the potential to have a aggressive profile within the oral GLP-1 house,” outgoing Pfizer Chief Scientific Officer Dr. Mikael Dolsten stated in a launch. Notably, the corporate didn’t observe any liver issues of safety in sufferers who acquired once-daily formulations of the drug.

Pfizer is one in all a number of drugmakers racing to win a slice of the marketplace for a extremely common class of weight reduction and diabetes medication known as GLP-1 agonists. Some analysts count on the business to be value roughly $100 billion by the top of the last decade. 

However Pfizer has thus far struggled to interrupt into the market.

The pharmaceutical large in December discontinued a twice-daily model of danuglipron after sufferers had hassle tolerating the drug in a mid-stage research. On the time, Pfizer stated early research information on the once-daily model would “inform a path ahead.” 

However traders have been pessimistic concerning the firm’s potential within the GLP-1 house ever because it scrapped a distinct once-daily tablet in June 2023 as a result of elevated liver enzymes in sufferers who acquired the remedy. These have been amongst a string of setbacks Pfizer confronted final 12 months on prime of the speedy decline of its Covid enterprise, which battered its inventory. 

Nonetheless, Pfizer has different experimental weight problems medication in early phases of growth. The corporate has not disclosed how these therapies will work. 

“Weight problems is a key therapeutic space for Pfizer, and the corporate has a sturdy pipeline of three scientific and a number of other pre-clinical candidates,” Dolsten stated within the launch.

Pfizer additionally believes GLP-1s are solely “scratching the floor of what we are going to see in weight problems,” CEO Albert Bourla stated throughout a convention in June. 

Pfizer’s danuglipron is a GLP-1 that promotes weight reduction in the identical approach as Novo Nordisk’s injection Wegovy and diabetes remedy Ozempic. The medication mimic a single hormone produced within the intestine known as GLP-1, which alerts to the mind when an individual is full.

Injections from Novo Nordisk and Eli Lilly have soared in demand over the past 12 months regardless of their hefty value tags and restricted insurance coverage protection. 

The pair – together with Pfizer and different drugmakers – have been racing to develop oral variations which are extra handy for sufferers to take and simpler to fabricate, which might assist alleviate provide shortages within the U.S. 

Pfizer has beforehand stated it might purchase or associate with a smaller weight problems drugmaker. 

Bourla advised reporters at a convention in January that it was unlikely the corporate would purchase an weight problems remedy in later-stage growth, particularly as the corporate focuses on chopping prices. 

However he stated Pfizer was on the lookout for potential licensing offers or earlier-stage weight reduction medication. 

Pfizer’s replace on danuglipron comes days after the corporate stated it’s looking for a successor to Dolsten, who will step down after greater than 15 years on the drugmaker. Dolsten performed a vital function in creating Pfizer’s Covid vaccine.